Pharma sales face multiple question marks in 2021, thanks to the pandemic and U.S. administration change, survey says

Pharma companies always worry about pricing and regulatory issues, but the pandemic added another layer of what-ifs last year.

From skyrocketing expenses and delayed drug approvals to regulatory and manufacturing stalls, the outsized effect of COVID-19 slammed pharma sales management.

As many companies have moved to value-based and outcome reimbursement models—57% in the past two years, according to data from revenue management service provider Model N—the pandemic arrived to change the game and push uncertainty and crisis management into overdrive.